<DOC>
	<DOCNO>NCT02930018</DOCNO>
	<brief_summary>The ESCAPE-NA-1 study design determine safety efficacy neuroprotectant , NA-1 , reduce global disability subject major acute ischemic stroke ( AIS ) small establish infarct core good collateral circulation select endovascular revascularization .</brief_summary>
	<brief_title>Safety Efficacy NA-1 Subjects Undergoing Endovascular Thrombectomy Stroke ( ESCAPE-NA1 )</brief_title>
	<detailed_description>Trial Objectives : The primary objective determine efficacy neuroprotectant , NA-1 , reduce global disability subject major acute ischemic stroke ( AIS ) small establish infarct core good collateral circulation select rapid endovascular revascularization . The secondary objective determine efficacy NA-1 : - Reducing functional dependence - Improving neurological outcome - Improving activity daily live - Reducing mortality rate The lead safety objective determine effect administer dose 2.6 mg/kg intravenous ( IV ) infusion NA-1 subject acute stroke select endovascular revascularization serious adverse event ( SAEs ) 90-day mortality . Trial Design : This study Phase 3 , randomize , multicentre , blind , placebo-controlled , parallel group , single-dose design . Subjects harbor acute ischemic stroke select endovascular revascularization accordance local institutional practice harbor small establish infarct core good collateral circulation give single , 2.6 mg/kg intravenous dose NA-1 placebo soon deem meet enrollment criterion start within 30 minute randomization . The randomization stochastic minimization balance baseline factor .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<criteria>1 . Acute ischemic stroke ( AIS ) immediate endovascular treatment 2 . Age 18 great . 3 . Onset ( lastseenwell ) time randomization time within 12 hour . 4 . Disabling stroke define baseline National Institutes Health Stroke Score ( NIHSS ) &gt; 5 time randomization . 5 . Prestroke ( 24 hour prior stroke onset ) independent functional status activity daily live modify Barthel Index ( BI ) &gt; 90 ( 95 100 ) . Patient must live home , apartment senior lodge nurse care require . 6 . Confirmed symptomatic intracranial occlusion , base multiphase dynamic computerized tomographic angiography ( CTA ) , one follow location : Intracranial carotid T/L , M1 middle cerebral artery ( MCA ) . Functionally , define M1 M2 , bulk MCA territory must ischemic . 7 . Noncontrast compute tomography ( NCCT ) CTA* trial eligibility perform repeat ESCAPENA1 stroke centre endovascular suite onsite . 8 . Endovascular treatment declare first endovascular approach either stent retriever aspiration device , intend initiate ( arterial access ) within 60 minute baseline/qualifying NCCT first recanalization 90 minute . Study drug intend administer within 60 minute baseline/qualifying NCCT . 9 . Signed informed consent subject legally authorize representative . 1 . Evidence large core establish infarction define ASPECTS 04 . 2 . Evidence absence collateral circulation CTA ( Collateral score 0 1 ) . 3 . Intent use endovascular device stent retriever clot aspiration device intraarterial medication initial thrombectomy approach . 4 . Intent use intravenous thrombolytic alteplase intravenous thrombolysis plan . 5 . No femoral pulse , difficult endovascular access extreme tortuosity great vessel predict result inability deliver timely endovascular therapy . Direct common carotid radial/brachial/axillary access permissible . 6 . Estimated known weight &gt; 120 kg &lt; 45 kg . 7 . Pregnancy ; woman childbearing potential urine serum beta human chorionic gonadotropin ( Î²hCG ) test positive , breastfeed . 8 . Severe contrast allergy absolute contraindication iodinate contrast prevent endovascular intervention . 9 . Clinical history , past image clinical judgment suggest intracranial occlusion chronic suspect intracranial dissection predict lack success endovascular intervention . 10 . Prior enrolment ESCAPENA1 trial prior receipt NA1 reason . 11 . Severe know renal impairment define require dialysis ( hemo peritoneal ) know creatinine clearance &lt; 29 mL/min . 12 . Patient severe fatal comorbid illness prevent improvement followup . 13 . Patient complete followup treatment due comorbid nonfatal illness know visitor city know reason followup would impossible ( e.g . incarcerate federal prison ) . 14 . Participation another clinical trial investigate drug , medical device , medical procedure 30 day precede study inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Acute Ischemic Stroke</keyword>
	<keyword>Endovascular Thrombectomy</keyword>
	<keyword>Neuroprotection</keyword>
	<keyword>Tat-NR2B9c</keyword>
	<keyword>NA-1</keyword>
</DOC>